MedImpact Healthcare Systems, Inc., the largest independent provider of health solutions, technology, and pharmacy benefit services in the U.S., announced today the expansion of access to Humira biosimilars—Simlandi and adalimumab-adaz—for new patients needing treatment for inflammatory conditions like Crohn’s disease or rheumatoid arthritis. Current patients using Humira can continue their treatment, while new patients who have tried either biosimilar without achieving desired results may switch to Humira.
“We are introducing these Humira biosimilars through the pharmacy benefit because, for the first time, we are confident they meet our rigorous standards for clinical interchangeability and the lowest net cost,” stated Nicole Ellermeier, PharmD, MBA, Vice President of Formulary Strategy & Rebate Economics at MedImpact. “Our approach is designed to provide members, providers, and payers with flexibility, options, and confidence.”
This move aligns with MedImpact’s 35-year commitment to pharmacy and manufacturer neutrality. Members have the flexibility to fill prescriptions for FDA-approved biosimilars at any pharmacy, regardless of the manufacturer—a level of choice not always available in the market. Given the complexity of biosimilar production and the risk of supply chain disruptions, MedImpact is ensuring the availability of two biosimilars to maintain supply continuity.
To prioritize clinical considerations over cost, the member copay, deductible, and other cost factors will be identical for both the biosimilars and Humira, enabling members to choose without facing additional out-of-pocket expenses.
MedImpact is also closely monitoring the biosimilars market for various conditions and will consider adding more to its formularies if they meet clinical, supply chain, and cost standards.
“Expanding access to biosimilars is a complex process with significant clinical and economic implications,” said Arpit Patel, PharmD, Vice President of Trade Relations at MedImpact. “Our guiding principle is simple: First, we ensure convenient and affordable access to clinically appropriate medications, and then we focus on making these medications financially sustainable for both patients and payers.
